Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Cannabis
- Drugs
- Cancer
- Medical
- Disease
- Therapeutic
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 318266
University is a pioneer in the research of the endocannabinoid system and the research to synthesize novel cannabinoids cannabinoid-based dual-action compounds and novel chemical derivatives based upon the molecular structure of existing cannabinoids. Both of these programs are intended to provide series of proprietary NCEs for evaluation as potential drug candidates.
Licensee is a biopharmaceutical company developing transformational therapeutics targeting immuno-oncology gene therapy for the treatment of multiple cancers through the research and development of the drug candidates,.
IPSCIO Record ID: 384961
Upon notice by Licensee to Licensor from time to time during the period permitted therefor pursuant to this Agreement, Licensor shall granted to Licensee under Collaboration IP and Licensor Background IP, without the need for further action by either of the Parties, an exclusive, license to make, have made, use, offer for sale, sell, import and otherwise exploit the Product Candidates referenced in such notices in the Territory in the Research Field.
Licensor of the United Kingdom grants to the Licensee of Japan under Licensor Background IP and Collaboration IP, the sole right to use the same in any way whatsoever for the purpose of the Research Collaboration including to research and use Research Compounds for the purposes necessary to perform its obligations and exercise its rights under the Research Plan but excluding the right to manufacture Research Compounds or have Research Compounds manufactured on its
behalf other than by Licensor. This right shall not be capable of sub-license.
Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.
Botanical Drug Candidate or BDC shall mean
— any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
— a combination of two or more Phytocannabinoid extracts described containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and
— any biological or chemical modification of the Phytocannabinoids including any metabolite or degradant.
Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid), or, outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).
Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).
Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabinoid but;
— which has been developed with information resulting from the Research Collaboration and,
— for which one or more patent· applications have been filed by Licensee on an invention conceived within three years following expiration of the Research Term or any Extended Research Term claiming a novel composition of matter and a cannabinomimetic or cannabinergic effect through direct, or indirect (i.e. modulation of related metabolic enzyme systems), effects on one or more cannabinoid receptors (including their allosteric sites).
Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.
Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.
IPSCIO Record ID: 372460
This agreement is for the research and early stage development of pharmaceutical preparations based upon Research Compounds (as defined below) for the treatment of CNS and cancer indications.
Research Compounds shall mean collectively, all Selected BDCs and Selected Drug Candidates. For clarity, Research Compounds shall include Synthetic Cannabinoids synthesized under the Research Plan and which subsequently become Selected BDCs and/or Selected Drug Candidates.
Botanical Drug Candidate or BDC shall mean
— any cannabinoid from a single chemovar of a chemically and genetically characterized Cannabis sativa plant (Phytocannabinoid) at any stage of research or development made using any extraction method and in any degree of purification in which only a single cannabinoid is present in a concentration which has the potential to be therapeutically active including, without limitation, the THC fraction and the CBD fraction separately; and
— a combination of two or more Phytocannabinoid extracts described above containing two or more Phytocannabinoids present in concentrations such that both have the potential to be therapeutically active mixed in a precise ratio i.e. the THC and CBD fractions mixed (without other fractions) in the ratio of THC CBD of 90 10. For clarity specifically excluded from the definition of BOC is any combination of the THC and CBD fractions when mixed (without other fractions) in a ratio of CBD to THC that falls inside the range of 2575 to 7525; and,
— any biological or chemical modification of the Phytocannabinoids in above including any metabolite or degradant.
Synthetic Cannabinoid shall mean any Phytocannabinoid produced by synthetic methods either pursuant to a Research Plan (a Type 1 Synthetic Cannabinoid) or outside of the Research Collaboration but with information resulting from the Research Collaboration (Type 2 Synthetic
Cannabinoid).
Synthetic Cannabinoid Product shall mean any pharmaceutical product containing a Type 1 Synthetic Cannabinoid (Type 1 Synthetic Product) or a Type 2 Synthetic Cannabinoid (Type 2 Synthetic Cannabinoid Product).
Synthetic Molecule shall mean a synthetic molecule whose chemistry is not based on a Phytocannabiooid but which has been developed with information resulting from the Research Collaboration and for which one or more patent.
Synthetic Molecule Product shall mean any pharmaceutical product containing a Synthetic Molecule.
The Research Field shall mean the treatment, diagnosis, prevention, or palliation of diseases, conditions, syndromes, and maladies of the central and peripheral nervous. systems of humans and animals and cancer in humans and animals.
IPSCIO Record ID: 219206
Licensee believes NEO1940 has promise as an anti-tumour therapy based upon the extensive literature on the anti-tumour effects of CB1 and CB2 agonists
Licensor is developing an orally available cannabinoid 1 and 2 (CB1/CB2) receptor agonist and the lead from a series of benzimidazole derivatives known as NEO 1940 for supportive care therapy in patients with cancer. NEO 1940 exhibits reduced brain penetration and is expected to induce desired cannabinoid effects without central nervous system side effects.
NEO 1940 is being developed to treat cachexia, cancer pain, nausea and vomiting, anxiety, insomnia related to cancer.
IPSCIO Record ID: 226030
Transferred Assets means
(I)
all Intellectual Property Rights in respect of the Compounds;
(ii)
all Books and Records belonging to the Vendor and relating to the Compounds; and
(iii)
all Transferred Technology.
Intellectual property rights in its novel cannabidiol quinone derivatives referred to as VCE-003 and VCE-004 based on the chemical backbones.
Transferred Technology means any Technology in respect of the Compounds.
Business means the Vendor’s business related to the research and development of new drugs and treatments based on non-psychotropic cannabinoids and their extracts and derivatives.
Compounds means all compounds included in Series 3 and Series 4 respectively.
* Series 3 means compounds based on or derived from the chemical backbone. VCE-003 is a cannabigerol-hydroxy-quinone derivative according to the formula. Compounds are derivatives of cannabigerol-hydroxy-quinone derivatives (CBG-Q derivatives) of Formula.
* Series 4 means compounds based on or derived from the chemical backbone. VCE-004 Backbone is the quinone ring has been numbered arbitrarily in order to show in which position of the ring the substituents replacement is made for rendering the CBD-Q derivatives.
Technology means technology and information of whatever nature or kind, in all cases whether or not subject to any Intellectual Property Rights and whether or not fixed in any medium or reduced to practice, including without limitation
(I)
inventions, formulae, product formulations, processes and processing methods, technology and techniques;
(ii)
trade secrets, copyrights, know-how, research and technical data; and
(iii)
software, studies, findings, algorithms, instructions, guides, manuals and designs, and papers or other related materials of any nature at all, whether written or otherwise.
Products means, in respect of the Compounds any drug manufactured and falling within the scope of any Intellectual Property Right of the Purchaser in respect of either of the Compounds.
Patents means collectively the rights in and to any and all inventions of the Vendor in respect of the Compounds that are disclosed in United States, Canada, Spain and/or other jurisdictions, domestic and foreign patents and patent applications.
Application number
PCT/ES 2010/070156 Cannabinoid Quinone Derivatives
Application number
PCT/2014/057767 Cannabidiol Quinone Derivatives
Application number
EP14156954.1 / PCT/EP2015/053032 Novel Cannabigerol Derivatives
Application number
PCT/EP2017/057389 CANNABIDIOL DERIVATIVES AS INHIBITORS OF THE HIF PROLYL HYDROXYLASES ACTIVITY
EHP-101, also known in the scientific literature as VCE-004.8, is a patented aminoquinone NCE derived from CBD. It has been modified to enhance the therapeutic benefits of CBD by having a dual PPAR? and CB2 agonist activity, and also by affecting the hypoxia inducible factor (HIF) pathway. These receptors have been shown in the scientific literature to be beneficial in preventing neuroinflammation and demyelination in the central nervous system, and fibrogenesis in the periphery.
IPSCIO Record ID: 293157
The license is to develop and commercialize certain patents in order to develop, manufacture, market, distribute, sell, repair and refurbish products, all within the use of the 2019 Hebrew Licensed Technology for (i) Cannabinoid phenolate metal salts, including mono, di and trivalent metals such as Li, Na, K, Ca, Mg, Zn, Fe and Al and their mixtures with native or synthetic cannabinoids, their pharmaceutical formulations, including for oral and topical administration; and (ii) pharmaceutical formulations, for the administration of cannabinoid chemical derivatives, including any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the “2019 Fieldâ€).
IPSCIO Record ID: 352096
Provisional Application No. 62/632,448
United States Application No. 16/612,472
